Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids
Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids
复制标题
DOI：
10.1006/abio.2001.5000
复制
发表时间：
2001-03-15
影响因子：
2.9
通讯作者：
Xu, Y
中科院分区：
文献类型：
--
作者：
Xiao, YJ;Schwartz, B;Xu, Y
溶血磷脂（lyso-PLs），包括各种甘油基和鞘氨醇基溶血磷脂，在许多生化，生理和病理过程中发挥重要作用。分析这些脂质的经典方法涉及气相色谱法和/或高效液相色谱法，这些方法耗时、繁琐，并且有时由于密切相关的脂质种类的不完全分离而不准确。我们现在描述的定量分析溶血磷脂酶的腹水样品卵巢癌患者使用电喷雾电离光谱。检测到三类新的溶血-PL分子：nUrvl-LPA、烯基-LPA和甲基化溶血磷脂酰乙醇胺。重要的是，与非恶性疾病患者相比，卵巢癌患者腹水中以下溶血磷脂种类显著增加（例如，肝功能衰竭）：LPA（包括酰基-、烷基-和烯基-LPA物质）、溶血磷脂酰肌醇和鞘糖基磷酸胆碱。溶血磷酰胆碱含量也显着不同的腹水从两组患者。然而，卵巢癌患者腹水样品中的总磷酸盐含量与非恶性疾病患者相比没有显著差异。(C)北京：科学出版社.
Lysophospholipids (lyso-PLs), including various glycerol-based and sphingosine-based lysophospholipids, play important roles in many biochemical, physiological, and pathological processes. The classical methods to analyze these Lipids involve gas chromatography and/or high-performance liquid chromatography, which are time-consuming, cumbersome, and sometimes inaccurate due to the incomplete separation of closely related lipid species. We now describe the quantitative analysis of lyso-PLs in ascites samples from patients with ovarian cancer using electrospray ionization spectrometry. Three new classes of lyso-PL molecules are detected: nUrvl-LPA, alkenyl-LPA, and methylated lysophosphatidylethanolamine. Importantly, the following lysophospholipid species are significantly increased in ascites from patients with ovarian cancer, compared to patients with nonmalignant diseases (e.g., Liver failure): LPA (including acyl-, Alkyl-, and alkenyl-LPA species), lysophosphatidylinositol, and sphingosylphosphorylcholine. Lysophosphorylcholine contents are also significantly different among ascitic fluids from the two groups of patients. However, the total phosphate content in ascites samples from patients with ovarian cancer is not significantly different compared to that from patients with nonmalignant disease. (C) 2001 Academic Press.